<DOC>
	<DOCNO>NCT02110264</DOCNO>
	<brief_summary>The aim trial ass clinical utility , effectiveness , cost implication treatment incarcerate offender opioid use disorder randomly assign one three treatment condition include depot formulation naltrexone ( XR-NTX , VivitrolÂ® ) ( XR-NTX ) , Vivitrol provide session patient navigator ( PN ) XR-NTX+PN , drug education procedure ( ETAU ) release community . This trial investigate whether effective medication therapy use non-incarcerated population also effective incarcerated individual . Empirical evidence demonstrate start treatment release greatly increase probability successful outcome include reduce alcohol drug use , increased employment rate , reduce recidivism rate .</brief_summary>
	<brief_title>Injectable Pharmacotherapy Opioid Use Disorders ( IPOD )</brief_title>
	<detailed_description>This randomize , open-label trial examine feasibility , efficacy , net economic benefit XR-NTX opioid addiction deliver without platform PN provide six month compare education ( ETAU ) condition . Before release jail , participant XR_NTX XR-NTX+PN condition receive first Vivitrol injection ( XR-NTX+PN condition meet Patient Navigator ) schedule medication management session twice monthly month 1-3 , monthly injection month 4-6 . Participants XR-NTX+PN condition meet PN provide behavioral assistance overcome possible barrier community outpatient treatment provide referral community treatment program . Participants ETAU condition receive education design reduce likelihood overdose schedule XR-NTX XR-NTX+PN group . Participants 150 individual , meet DSM-5 ( via CIDI-2 ) criterion opioid use disorder , 18 year old , detoxified opioids Metropolitan Detention Center Albuquerque , New Mexico . This study include participant study physician determines possible treatment study drug best interest , inform consent obtain . All participant schedule twice-monthly medical management assessment appointment first three month 24-week post-release intervention phase , monthly appointment month 4-6 . Eligible participant randomly assign treatment condition ( XR-NTX , XR-NTX+PN , ETAU ) equal number . XR-NTX XR-NTX+PN participant undergo naloxone challenge ensure opioid abstinence time Vivitrol induction . Those XR-NTX+PN condition provide aPN facilitate attendance outpatient treatment program well assist need . The ETAU group receive medication schedule assessment education drug abuse , maintain abstinence , method avoid overdoses schedule two group . All group also provide referral community-based substance abuse treatment program .</detailed_description>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Be least 18 year age old , 2 . Meet criterion DSM5 opioid use disorder , 3 . Be detain least 48 hour , 4 . Have expect release date within one year , 5 . Plan reside area release . 1 . Have medical ( e.g. , liver failure , congestive heart failure ) psychiatric condition ( e.g. , suicidal ideation , psychosis ) would make participation unsafe judgment medical staff PI , 2 . Have current chronic pain plan undergo pain treatment/therapy , 3 . Have know sensitivity naltrexone naloxone , 4 . Have participate investigational drug study within past 30 day prior screen , 5 . Be nurse pregnant female , agree use medically acceptable form birth control oral contraceptive , barrier ( diaphragm condom ) , levonorgestrel implant , intrauterine progesterone contraceptive system , medroxyprogesterone acetate contraceptive injection , complete abstinence . Females become pregnant course study withdrawn study , request , provide referral drug treatment and/or medical care , 6 . Have pending legal action could prohibit continued participation 24week intervention period study , legal proceeding could possibly result incarceration , 7 . Have current pattern alcohol , benzodiazepine , depressant sedative hypnotic use , determine study physician would preclude safe participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Opioid Use</keyword>
	<keyword>Incarceration</keyword>
	<keyword>Vivitrol</keyword>
	<keyword>Patient Navigator</keyword>
	<keyword>Drug Education</keyword>
</DOC>